Private View: Animals in Advertising

Evan Young
Evan Young

Borrowed interest in advertising is an occasional flashpoint for heated discussions around the proverbial water cooler. In a global sense, use of unrelated metaphor or techniques to grab attention for a brand can be a mixed bag. It can be hilarious or awe-inspiring, but if your audience doesn't connect it to the brand, then you've flopped.

Some creative professionals rail from the pulpit against use of borrowed interest. Others listen to these diatribes and shrug—meh!—then turn back to their elephant concept.

Me? I like animals. Not in the crazy cat guy sense, but for pure visual impact, animals are exceptionally fascinating to look at. Ditto for insects. Fruit. Cool robots. Clay. Yarn. Goo. Whatever.

Any of these objects might have a metaphorical hook that provides a perfect entrée to the efficacy, MOA, pharmacokinetics, or QoL impact of a brand. All is fair game, it just has to make sense.

In other words... don't give me a lung cancer Chimp. Give me an allergy Bee.

And with that segue, I present (in the above slideshow): Animals in Advertising.  


Evan Young is associate creative director at Renavatio Healthcare Communi­cations.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.